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Psoriatic arthritis (PsA) is a chronic inﬂammatory skin disease that causes enthesitis and destructive arthritis and signiﬁcantly
lowers patient quality of life. Recognition of the two target organs (the skin and joints) involved in the immunopathophysiology of
PsA helped in elucidating the pathology of various systemic autoimmune diseases targeting multiple organs. Recent advances
in immunology and genetics have made it clear that acquired immunity, especially that mediated by the Th17/IL-23 axis,
plays an important role in the inﬂammatory pathology observed in psoriasis and PsA. Additionally, involvement of natural
immunity has also been suggested. Microbial infection has been known to trigger psoriasis and PsA. Recent clinical studies using
biopharmaceuticals, such as tumor-necrosis-factor- (TNF-) α inhibitors and IL-12/23 p40 antibodies, indicate that studies need
not be based only on the immunological phenomena observed in PsA pathology since disease pathology can now be veriﬁed
using human-based science. Considering this aspect, this paper discusses the immunopathology of PsA compared to psoriasis
(cutaneous) and rheumatoid arthritis in humans and immunopathology of PsA with respect to the Th17/IL-23 axis and microbial
infection.
1.Introduction
Psoriasisisatypicalinﬂammatorykeratosis,characterizedby
inﬂammation, telangiectasia, hyperproliferation, and abnor-
mal diﬀerentiation of epidermal cells, and it is sometimes
complicated by arthritis. There is considerable variation in
reports concerning the transition from psoriasis to psoriatic
arthritis (PsA), with ﬁgures ranging from 6% to 42%.
The onset of cutaneous psoriatic eruptions usually precedes
that of PsA; a study involving 1000 patients with PsA
showed that cutaneous eruptions preceded the onset of
PsA in 86% of cases by more than 12 years [1, 2]. PsA
often causes destructive arthritis and arthropathy, which
considerably decrease patient quality of life. Thus, clinicians
must anticipate when patients with psoriasis vulgaris will
progress to arthropathic psoriasis and intervene decisively
in the early stages of onset of arthropathy, therapeutically
targeting psoriatic skin and joint inﬂammation.
Psoriasis can aﬀect two target organs—the skin and syn-
ovial membrane—and its main pathogenesis is considered
to be chronic inﬂammation. The cause of this disease is
probably based on the common foundations of autoimmune
or autoinﬂammatory pathology. The mechanism by which
this occurs begins with antigen-presenting cells, which are
presumed to activate cutaneous and synovial membrane T
cells, although the autoantigens important for this process
remain unclear. These activated T cells then move from
circulation to the target organs, and chronic inﬂammation
occurs in the skin and synovial ﬂuid. This process is
considered to occur before the onset of clinical symptoms.
To date, studies have indicated several key diﬀerences
between the inﬂammatory pathology of psoriasis and PsA.
Because the pathology of PsA diﬀers from that of cutaneous
psoriatic lesions and at present it is diﬃcult to obtain
synovial samples for pathological analyses, elucidation of the
pathology of associated arthropathy is lagging behind that of
cutaneous eruptions. In patients with PsA, cutaneous erup-
tions and arthropathy do not necessarily exhibit the same
disease characteristics, and their pathological relationship
remains unclear.
Causes of psoriasis and PsA remain unclear, although
newdisease-susceptibility geneshaverecentlybeenidentiﬁed
through genome analysis [3]. These discoveries have high-
lighted the importance of natural immunity, particularly in2 International Journal of Rheumatology
the immunopathology of T cells and cytokines, especially T
helper (Th) 17 cells. In addition, the introduction of
biopharmaceuticals for treatment of autoimmune diseases
has contributed considerably to elucidation of pathology
of rheumatism and psoriasis. Targeted therapy, focused on
anticytokine preparations, has recently been introduced
for treatment of various autoimmune diseases including
rheumatoid arthritis (RA), and dramatic results are being
obtained.
PsA is no exception. The use of biopharmaceuticals, such
as tumor-necrosis-factor- (TNF-) α inhibitors, for treatment
of psoriasis and PsA is leading to a paradigm shift [4–6].
Although the immunopathology of PsA, involving both
cutaneous and synovial targets, is complex, genome analysis
andtargetedtherapywithbiopharmaceuticalshaveincreased
our understanding of the immunopathology of PsA.
This paper discusses the immunopathology of PsA by
comparing the pathology of PsA with that of cutaneous
psoriaticlesionsandRA,arepresentativeexampleofautoim-
mune arthritis, to provide a better understanding of this
subject.
2. CD4+T CellsinPsoriasis
T-cell suppression treatment for psoriasis in humans has
shown that T cells play an important role in psoriatic pathol-
ogy. T-cell activation inhibitors, including cyclosporine,
IL-2 toxin, and Alefacept (lymphocyte function-associated
antigen-3-Ig LFA-3-Ig), have been used to successfully treat
psoriasis,indicatingthatTcellsareintimatelyinvolvedinthe
pathology of this disease.
An interesting study involved the transplantation of
unaﬀected skin of a patient with psoriasis to SCID (severe
combined immune deﬁciency) mice. The introduction of
activated CD4+ T cells induced cutaneous psoriatic lesions,
although the same did not occur with CD8+ T cells. This
additionally clariﬁed the signiﬁcant role of CD4+ T cells in
the onset of psoriasis [7].
Th1 cells have previously been considered to be signiﬁ-
cantly involved in psoriasis because of the large number of
interferon-gamma- (IFN-γ-) producing cells observed in
areas of cutaneous eruptions. However, the discovery of IL-
17-producinghelperTcells(Th17cells)[8]madeitclearthat
these were the cells most signiﬁcantly involved in psoriasis
[9–11].
3. The Role of the Th17/IL-23 AxisinPsoriasis
Th17 cells are a newly identiﬁed subset of helper T cells
that produce interleukin- (IL-) 17A, IL-17F, IL-21, and IL-22
[12] and diﬀer functionally from Th1 and Th2 cells. Anal-
ysis of IL-17-deﬁcient mice [13] suggested that speciﬁc con-
ditions previously considered to be suppressed by Th1 cells,
including speciﬁc infections and autoimmune diseases
(e.g., autoimmune arthritis [14], experimental autoimmune
encephalomyelitis (EAE), and psoriasis [15]) may actually be
inhibited by Th17 cells. Like Th1 and Th2 cells, Th17 cells
appeartohaveevolvedtoinduceacquiredimmuneresponses
againstmicrobes,suchasbacteria.AbnormalTh17responses
are believed to play a signiﬁcant role in the onset of various
autoimmune diseases.
T h eT h 1 7c e l ll i n e a g ed i ﬀers from that of Th1 and
Th2 cells. Orphan Nuclear Receptor RORγt (retinoid-related
orphan receptor gamma t) have been identiﬁed as speciﬁc
Th17 transcription factors [16]. RORγtc o o p e r a t e sw i t h
signal transducer and activator of transcription 3 (STAT3) to
induce production of IL-23 receptors, which play an impor-
tant role in maintenance and ampliﬁcation of Th17 cells.
IL-23 receptors promote IL-17 transcription and Th17 cell
diﬀerentiation via enforced RORγt expression.
IL-23 is a member of the IL-12 cytokine family, which
forms a heterodimer comprising p40 and p19 subunits. It is
produced by antigen-presenting cells, such as dendritic cells
and macrophages.
IL-23 also binds to receptors to which the IL-12Rβ1a n d
IL-23R subunits have already been bound. IL-23 acts on cells
that have diﬀerentiated into Th17 cells, potentiating RORγt
activity, and participates in maintenance and proliferation of
Th17 cells. Induction of Th17 cells alone by IL-6 and TGF-β
results in production of IL-10, which inhibits inﬂammation.
However, IL-23 causes inherent activation of Th17 eﬀector
cells [17, 18]. If IL-23 levels are low, then Th17 cells will be
absent and IL-17 production will be scarce [19, 20]. Thus,
IL-23isindispensableforTh17eﬀectorfunctionsinimmune
disorders and maintenance of Th17 cells.
Numerous studies analyzing psoriatic cutaneous lesions
revealed that the Th17/IL-23 axis is important in psoriasis
pathogenesis. Th17 cells secrete IL-22 in addition to IL-17,
with increased IL-17 and IL-22 levels seen in psoriatic areas
[21–25]. These cells can also increase serum and cutaneous
eruption site IL-23 expression in psoriatic patients [26], and
increased number of Th17 and Th22 cells (CD4+ T-helper
cell subset that produces IL-22, but not IFN-γ or IL-17) have
also been observed [27]. Expression of the surface markers
IL-23R and CC chemokine receptor (CCR) 6, considered to
be involved in pathogenesis, is also seen with these Th17
cells. Th22 cells are believed to be especially involved in skin
inﬂammation.
Cytokines, such as IL-22, IL-9, and IL-20, that are
produced by Th17 and Th22 cells can activate STAT3 in epi-
dermal keratinocytes and inhibit their diﬀerentiation, while
promoting cell migration and proliferation [23, 28–30].
It has also been conﬁrmed experimentally that these cytok-
ines induce inﬂammatory chemokines and promote cuta-
neous acanthosis and parakeratosis [15, 24].
As mentioned previously, IL-23 is a cytokine that is
necessary for the function and maintenance of Th17 eﬀector
cells. Dermal myeloid dendritic cells play an important role
in activation of Th17 cells, which are involved in psoriatic
lesionformation,throughproductionofIL-23andIL-23p19
protein [26, 31–34]. These dendritic cells are also known to
produce IL-23 in a TNF-α-dependent manner [35].
The above observations suggest that acanthosis present
in psoriasis is caused by activation of STAT3 in keratinocytes,
which mediates production of IL-22 (Th17/IL-23 axis eﬀec-
tor molecule). Although IL12B, IL23R, and IL23A have beenInternational Journal of Rheumatology 3
identiﬁed as psoriasis susceptibility genes, genetic polymor-
phism has been suggested in the Th17/IL-23 axis that pro-
motes genetic predisposition [36].
Psoriasis improves dramatically after administration of
the IL-12/23 p40 monoclonal antibodies ustekinumab and
briakinumab [37–40]. Because clinical psoriatic symptoms
improve and IL-23 levels decrease after treatment with
narrow-bandultraviolet-B(NB-UVB)andTNF-αinhibitors,
a relationship between excess production of IL-23 and
activation of psoriatic disease is indicated [26, 41, 42].
Furthermore, administration of anti-IL-12/23 p40 anti-
bodies results in improvements in psoriasis because they
inhibittheTh17/IL-23axis.However,sinceTNF-αinhibitors
also aﬀect production of IL-23 by acting on dermal myeloid
dendritic cells, it has been determined that these antibodies
inhibit IL-23/Th17 signals [37, 43].
4. The Th17/IL-23 AxisinPsoriaticArthritis
The importance of Th17 cells, IL-23, and Th22 cells in the
immunopathology of psoriasis has been previously deter-
mined using mice. Can this also be the case for PsA?
Studies involving mouse models are being used to
establishtherolesofTh17cellsinarthritis,includingRA,and
as pathogenic cells for many autoimmune and chronic in-
ﬂammatory diseases. Although T17 cells have been deter-
mined to play an important role in pathology of arthritis
using mouse models, involvement of Th17 cells and related
cytokines in human arthritic disease, including RA, cannot
be called deﬁnitive. In fact, clinical trials with an anti-IL-
17 neutralizing antibody (LY2439821) for RA, with arthritis
as the key therapeutic target, are currently being conducted
[44]. Despite observing signiﬁcant improvements, eﬀects
are inconclusive when compared to the dramatic results
obtained with TNF-α inhibitor treatment.
Similar to dermal cutaneous psoriatic eruptions, signiﬁ-
cant inﬁltration of the inﬂamed synovial membrane by acti-
vated CD4+ T cells is observed in PsA [45]. Fibroblasts and
T cells in synovial ﬂuid in PsA induce osteoclastogenesis and
bone resorption, leading to destructive arthritis via their
interactions with receptor activators of nuclear factor κB
(RANK), its ligand (RANKL), TNF-α, and IL-7. In vitro
analysis revealed that IL-23 exhibited osteoclastogenesis in-
ductiveactivities[2, 46] on IL-17, TNF, and RANKL through
an independent mechanism [47]. As stated previously,
treatment of psoriasis with IL-12/23 p40 antibodies has been
dramatically successful. A phase II clinical trial also found
signiﬁcant improvement in terms of the eﬀects of as an
IL-12/23 p40 antibody (ustekinumab) on PsA [48]. This
suggests the pathological roles of IL-23 in potentiation of
osteoclastogenesis and bone erosion in PsA-aﬀected joints.
Although immune responses mediated by IL-17 and IL-23
are not as apparent as with TNF-α, Th17 cells appear to play
an important role in PsA. The immunopathology of
PsA/psoriasis, including the Th17/IL/23 axis, is shown in
Figure 1.
5.Characteristicsofthe Immunopathology
of PsA Synovitis
We have mainly discussed the immunopathological diﬀer-
ences between inﬂammation in cutaneous psoriatic erup-
tions and synovitis. Organs exhibit diﬀerences in their in-
ﬂammatory reactions; however, this alone cannot explain
the precise pathology of PsA. Another useful approach is
conﬁrmation of the key diﬀerences between RA (the main
pathology of which is arthritis) and PsA. At present, RA can
be treated using various biopharmaceuticals and pathology
of RA is better elucidated than that of PsA. Conﬁrmation
of the key diﬀerences between PsA and RA synovitis will be
extremely useful for developing new treatment strategies for
PsA.
PsA synovitis is indicated by hyperplasia of the synovial
lining cells and mononuclear cell inﬁltration, similar to the
pathological changes observed in RA [45]. Like RA, ectopic
lymphoid neogenesis occurs in the inﬂamed synovial lining
in PsA, and there are peripheral lymph node addressin-
positive high endothelial venules (HEV, PNA d + HEV)
accompanied by the expression of the chemokines CXC
chemokine ligand (CXCL) 13 and CC chemokine ligand
(CCL)21.Microanatomicalbasesforgerminalcenterforma-
tion are known to exist in PsA [49].
Pathologically, therefore, no characteristic ﬁndings are
apparent when compared to other types of synovitis, al-
though there are key diﬀerences between RA and PsA
synovitis. In PsA, the lining layer is relatively thinner than in
RA, the sublining layer shows signiﬁcant inﬁltration of both
T and B cells, and it is characterized by vascular proliferation
and proliferation of synovial lining cells.
Cytokines in the synovial ﬂuid have also been compared,
and Th1 cytokines (TNF-α,I L - 1 β, and IL-10) were found at
higher levels in PsA than in RA synovial lining samples.
Proinﬂammatory cytokines, such as IFN-γ, IL-12, IL-15, IL-
17, and IL-18, also exhibited a higher level of expression in
PsA synovial tissue samples. Fibroblasts from the skin and
jointsofpatientswithPsAarehighlyproliferativeandsecrete
the cytokines IL-6, IL-1, and platelet-derived growth factor
(PDGF) [50–53].
A study by Kruithof et al. compared the immunological
and pathological features of synovitis in spondyloarthropa-
thy(SPA),whichincludesbothRAandPsA[54].Theyfound
that the tissue in this disease was highly vascularized with an
increased number of neutrophils and CD163-positive ma-
crophages. In contrast, thickening of the lining layer and
an increased number of CD83-positive dendritic cells were
more often seen in RA. Thus, it appears that the mechanisms
causing synovitis diﬀer between these two diseases.
Clinically, onset of PsA has been determined to occur as
enthesitis. Its pathology is considered to be more similar to
that of SPA than to RA [2]. In a previous study [54], intra-
cellular staining of tissue samples revealed intracellular
citrullinated proteins in 44% of patients with RA and major
histocompatibility complex (MHC) human cartilage gp39
peptide complexes (MHC-HC gp39) in 46%. These were not
observed in samples from patients with PsA or SPA. Thus, in
addition to its clinical picture, PsA is also immunologically4 International Journal of Rheumatology
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Figure 1: Th17/IL-23 axis, environmental factors and psoriatic arthritis. Environmental factors, such as microbial infections, Koebner
phenomenon, trigger Th17/IL-23 and CD8+ Tcells activation. Pro-inﬂammatory cytokines secreted by activated T cells promote
inﬂammation and induce acanthosis, parakeratosis, and spondyloarthropathy.
and pathologically more similar to SPA than RA. As we
described in the previous chapter, Th17/IL-23 axis plays an
importantroleinimmunepathogenesisofpsoriasisandPsA.
This also corresponds to the fact that there are greater
increasesinthenumberofperipheralbloodTh17cellsinSPA
than in RA [55].
Clinically, enthesitis observed in other types of SPA is
present in PsA, and it has been predicted that inﬂamma-
tion of the synovial lining adjacent to the entheses will
subsequently occur in rapid succession. The synovio-
entheseal complex (SEC) is therefore conceptualized as the
primary target tissue in PsA [56]. Although nail lesions
often accompany PsA, McGonagle et al. considered that the
nail matrix could be included in a broad deﬁnition, that is,
enthesitis of distal interphalangeal (DIP) joints, because
althoughtheﬁbroustissuecontinuingfromtheDIPextensor
tendon did not attach to the bone, it continued from the nail
matrix [57]. Fibers anchored to the nail plate adhere to the
synovial lining and penetrate the nail bed. Nail lesions occur
as a result of this enthesitis, indicating the presence of DIP
joint lesions.
6. MicrobialInfectionsandOnset of
Psoriasis and PsA
Disease susceptibility genes in the HLA-B locus, such as
HLA-B27, are common in SPA, such as reactive arthritis
and ankylosing spondylitis. The HLA-B susceptibility genes
HLA-B38, HLA-B39, HLA-B27, and MICA (major-his-
tocompatibility-complex-class-I-related chain A) have been
reported to be associated with PsA [3]. Onset of SPA is
known to be triggered by microbial infection. Here we
outline the factors responsible for PsA and psoriasis caused
by microbial infections and activation of natural immunity.
Many studies have investigated the relationship among
microbial infections, psoriasis, and PsA. In psoriasis, which
is the basis for PsA, Candida levels in the salivary gland,
alimentary canal, and feces of patients are higher than
those in healthy subjects [58, 59]. These Candida antigens
may lead to psoriatic lesions. We previously stated that
an immune reaction via the Th17/IL-23 axis plays an
important role in psoriatic lesions and that Candida albicans
(Candida infection) can induce production of Th17 cells,
These reactions are heavily dependent upon C-type lectin
receptors, such as Dectin-1 and Dectin-2 [60–63], and are
indispensable for inducing Th17 cells.
Extrinsic trigger factors are also important in PsA. Bac-
teria and viruses are particularly important microorganisms.
Asisthecasewithpsoriasis,β-hemolyticgroupAStreptococci
are initial causes of onset of PsA. However, in comparison
to psoriasis, PsA is rarely triggered by streptococci and is
nonspeciﬁc [64].
Prinz indicated that in psoriasis and PsA, psoriatic
pathology may be triggered by streptococcal antigens and
molecular mimicry of epidermal autoantigens [65]. As the
superantigens from Staphylococcus aureus, Streptococci,a n d
Candida can all stimulate T-cells, it is possible that T cell
stimulation by superantigens is responsible for pathology of
psoriasis.International Journal of Rheumatology 5
7.ActivationofNaturalImmunityand
Psoriasis/PsA
Although medicines rarely trigger these diseases, IFN-α is
a well-known trigger [66]. Furthermore, psoriatic exacerba-
tion and formation of new cutaneous eruptions have been
reported to be caused by administration of IFN-α during the
treatment of hepatitis C. Additionally, imiquimod, an analog
of Toll-like receptor (TLR) 7, while not directly exhibit-
ing antiproliferative activity on viruses, can act on TLRs
expressed by monocytes and dendritic cells to promote
production of cytokines, such as IFN-α,T N F - α,a n dI L -
12. It chieﬂy inhibits viral proliferation via IFN-α action.
Cutaneous psoriatic eruptions can be induced at external
imiquimod sites. This mechanism is considered to involve
inﬁltrationofnumerousplasmacytoiddendriticcells(pDCs)
in the dermis [67]. Activated pDCs produce large amounts
of IFN-α, which then stimulates myeloid dendritic cells to
activate autoimmune T-cell subsets, such as Th17 and Th1,
thus inducing psoriatic lesions.
The cutaneous-derived antimicrobial peptide LL-37 also
causes psoriatic lesions through the same mechanism. It
has been reported that LL37-mediated TLR9 signaling after
aggregation with autogenous DNA and activation of pDCs
resulted in the onset of psoriasis [68]. Greater production of
LL-37 than in the psoriatic epidermis causes the completion
of a positive feedback loop, after which the IL-23/Th17
system is activated. This suggests a link between natural
immunity and acquired immunity that causes onset of
psoriatic.
The types of psoriatic pathology exacerbation caused by
natural immunity do not necessarily constitute evidence for
PsA exacerbation. However, trauma has been reported to
promote PsA [69]. PsA is an arthropathy in which early
onset of enthesitis is often present. It has been hypothe-
sized that traumatic stimulation (Koebner phenomenon) of
enthesis activates natural immunity mediated by TLRs,
which initiates arthropathy. The details of this internal
Koebner phenomenon remain unclear, but involvement of
cutaneous psoriatic lesions, increased substance P in the
synovial lining, and neuropeptides has been indicated [70].
Microbial psoriasis and activation of natural immunity
induce Th17 and Th1 cells, which exacerbates autoimmune
pathology. This mechanism is an important phenomenon
that indicates a relationship between natural immunity and
acquired immunity in autoimmune diseases, and we hope
that this will be further elucidated in the future.
8.CD8+TCellsandPsA
There is an interesting report regarding the relationship
of PsA with microbial infection that is suggestive of PsA
pathology. The number of CD4+ T cells in HIV infection is
considerably reduced. Thus, in systemic autoimmune dis-
eases, such as RA and systemic lupus erythematosus (SLE)
in which CD4+ T cells play an important role, reduced
number of CD4+ T cells due to HIV infection can decrease
disease activity and direct a patient toward improvement.
This reduction in cell number is unfortunately not seen in
PsA [71].
This suggests that pathology of PsA diﬀers substantially
from that of RA and SLE. It has been hypothesized that in
PsA, activation of CD8+ T cells caused by activation of nat-
ural immunity is as important as cytokine- and microbial-
derived activation. CD4+ and as CD8+ T cells are considered
to play important roles in the skin and joints in PsA [72, 73].
Thisisalsosuggestedbytheresultsofgeneticanalysesfor
causative genes of both psoriasis and PsA, such as genome-
wide association studies (GWAS). These results showed that
HLA-Cw0602 was a disease-susceptibility gene with one of
the highest levels of sensitivity [3]. HLA-B38, HLA-B39,
HLA-B27, and MICA are known to be important in onset of
PsA and are more speciﬁc for PsA than for psoriasis. In both
diseases, however, these genes are found at the HLA-B
locus, which suggests that CD8+ T cells are pathologically
important.
Although it has not yet been determined how CD8+
T cells are involved in PsA, they appear to be mainly, or
partially, involved in potentiating production of cytokine in
the synovial lining and skin. The potentiation of inﬂamma-
tory cytokines, such as IL-1β, IL-2, IL-10, IFN-γ,a n dT N F -
α, has been observed in the synovial ﬂuid of patients with
PsA. These cytokines induce ﬁbroblast proliferation in the
synovial lining, thus promoting ﬁbrosis [52, 53, 72], that
probably contribute to joint stiﬀness and ankylosis.
Furthermore, osteoclastogenesis has also been suggested
to be potentiated. This would aﬀect bone turnover when
these proinﬂammatory cytokines activate T cells, and upreg-
ulated expression of the osteoprotegerin ligand [74].
9. Conclusion
Recent advances in immunology have clariﬁed the patholog-
ical roles of a newly identiﬁed subset of helper T cells, Th17
cells, and IL-23 in autoimmune diseases. Among numerous
autoimmune diseases, these discoveries have contributed
most to the elucidation of pathology of psoriasis and PsA.
PsA is immunologically more similar to SPA than to RA.
It is triggered by microbial infections, activation of natural
immunity, and functional mechanical stress at the site of
enthesis. Like psoriasis, acquired immunity involving the
Th17/IL-23 axis is considered to play an important role
in PsA. However, diﬀerences have been suggested between
arthritis-speciﬁc pathology and cutaneous psoriatic lesions.
T h e r eh a v ea l s ob e e na d v a n c e si na n a l y s e so fh u m a n
disease-susceptibility genes, including GWAS and
development of targeted therapy using biopharmaceuticals.
Theseresultsindicatethatelucidationofpathologyofhuman
immune diseases can now move past simple accounts of
immunological phenomena and veriﬁcation involving
mouse models. Accordingly, pathology of human diseases
can now be veriﬁed by human-based science.
In addition to the evaluation of joints, elucidation of
pathology of psoriasis is progressing more rapidly than for
arthritis since cutaneous lesions from clinical specimens can
be easily collected and therapeutic responses can be easily6 International Journal of Rheumatology
observed. Thus, although PsA is a rare disease, comparisons
and understanding cutaneous inﬂammation and pathology
of PsA have made it possible to make discoveries that would
be diﬃcult to detect with joint-based investigations alone.
This has contributed not only to elucidation of pathology
of PsA but also to that of other autoimmune arthritis. In
addition to advances in immunology, feedback, GWAS, and
treatment eﬀects of biopharmaceuticals are believed to help
in elucidation of pathology of PsA in humans.
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